Home › Funds › Weiss Asset Management LP › BBIO

Weiss Asset Management LP position in BBIO

BRIDGEBIO PHARMA INC · Health Care

Weiss Asset Management LP reported holding 320,184 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q2 2026 13F filing — a position valued at US$23.8M, representing 0.43% of its reported portfolio and ranking #48 among its reported holdings. Weiss Asset Management LP has disclosed BBIO holdings in 10 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)320.18K sh
Reported value held$23.85M
Portfolio Weight0.43%
First reportedQ4 2023
Last changeNew
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Weiss Asset Management LP's BBIO position evolved

Weiss Asset Management LP first disclosed a stake in BBIO in Q4 2023 at 7,000,000 shares (US$8.5M). The position peaked in Q3 2025 at 67,624,000 shares, worth US$94.9M. Across 10 filings, Weiss Asset Management LP increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 320,184 shares valued at US$23.8M. Notable position changes include a 275% increase in Q1 2024 (shares fell 18% over the following quarter), a 100% trim in Q1 2025 (shares rose 25% over the following quarter), a 6762399900% increase in Q2 2025 (shares rose 20% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 7.00M $8.46M New
Q1 2024 26.27M $21.59M Add
Q2 2024 46.87M $37.84M Add
Q3 2024 53.66M $55.30M Add
Q4 2024 33.09M $34.75M Reduce
Q1 2025 1 $35 Reduce
Q2 2025 67.62M $84.59M Add
Q3 2025 67.62M $94.91M Hold
Q4 2025 8.61K $658.81K Reduce
Q2 2026 320.18K $23.85M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 48 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has Weiss Asset Management LP held BBIO?

Weiss Asset Management LP has disclosed BBIO holdings in 10 of the last 11 reported quarters, going back to Q4 2023.

What is Weiss Asset Management LP's current position in BBIO?

As of Q2 2026, Weiss Asset Management LP holds 320.18K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $23.85M, representing 0.43% of its reported portfolio and ranking #48.

Has Weiss Asset Management LP been buying or selling BBIO?

In the latest 13F filing (Q2 2026), Weiss Asset Management LP newly opened its position in BBIO. The position peaked in Q3 2025 at 67.62M shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.